Immunocore Holdings (IMCR) Other financing activities (2023 - 2026)

Immunocore Holdings (IMCR) has reported Other financing activities for 4 consecutive years, with $656000.0 the latest figure, recorded in Q1 2026.

• Quarterly Other financing activities fell 74.28% year-over-year to $656000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (up 191.24% YoY) and the FY2025 annual result came in at $12.4 million, up 81.93% from the prior year.
• Other financing activities retreated to $656000.0 in Q1 2026 per IMCR's latest filing, from $4.3 million in the prior quarter.
• Over the last five years, Other financing activities for IMCR reached as high as $11.6 million in Q2 2023 and fell as low as $198000.0 in Q3 2024.
• A 4-year average of $4.2 million and a median of $3.7 million in 2025 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2024 — Other financing activities tumbled 98.09% — and 2025, when it soared 1131.54%.
• Year by year, Other financing activities stood at $6.3 million in 2023, then plunged by 91.21% to $550000.0 in 2024, then soared by 678.91% to $4.3 million in 2025, then plunged by 84.69% to $656000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $656000.0, $4.3 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.